By Colin Kellaher

Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its Spravato nasal spray for adults with treatment-resistant major depressive disorder.

The drug maker said the recommendation covers Spravato in combination with a selective serotonin reuptake inhibitor or serotonin and norepinephrine reuptake inhibitor for adults with treatment-resistant depression, meaning they haven't responded to at least two different treatments.

The European Commission, which generally follows the CHMP's recommendations, is expected to make a final decision by the end of the year, Janssen said.

The U.S. Food and Drug Administration in March approved Spravato for patients with treatment-resistant depression. The nasal spray is a close chemical relation to ketamine, an anesthetic that is often abused as a party drug but has been shown to have a fast-acting impact on depression symptoms.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

October 18, 2019 07:55 ET (11:55 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson